Investing.com -- Vistagen (NASDAQ:VTGN) stock plunged 78.8% Wednesday after the company announced its Phase 3 study of fasedienol for social anxiety disorder failed to meet its primary endpoint.

Moves by President Donald Trump to bring down costs for consumers risk alienating agricultural sector, a key voting bloc on ...

Bitcoin markets are losing some of their heat in mid-December after witnessing a frantic November. Both centralized exchanges ...

Bally’s Corporation (NYSE: BALY) has faced a notable shift in sentiment following a downgrade by Barclays analyst Brandt ...

The Australian sharemarket has taken a dip for a third consecutive day after new jobs data failed to provide hope of further interest rate cuts in the United States and oil fell to its lowest level in ...

The asset management company, which was founded by former Republican Presidential candidate and current Ohio state ...

This was not a space in which you wanted to be invested. There were a few exceptions, weirdly mostly in the motor vehicle space, but you were getting better returns pretty much anywhere else on the ...